SNDX
What one share of Syndax Pharmaceuticals holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.
Syndax Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.87 |
|---|---|
| Profit | −$2.51 |
| Cash and investments | $3.77 |
| Debt | $2.74 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.08 | −$3.22 | $0.02 | −$2.42 | — | $4.62 |
| 2017 | $0.10 | −$2.90 | $0.00 | −$2.26 | — | $4.28 |
| 2018 | $0.06 | −$2.92 | $0.01 | −$2.71 | — | $2.14 |
| 2019 | $0.05 | −$1.84 | — | −$1.66 | — | $1.16 |
| 2020 | $0.04 | −$1.87 | $0.00 | −$1.73 | — | $5.27 |
| 2021 | $2.61 | $0.46 | $0.00 | $0.54 | — | $7.43 |
| 2022 | $0.00 | −$2.46 | $0.00 | −$2.20 | — | $6.86 |
| 2023 | $0.00 | −$2.98 | $0.00 | −$2.28 | — | $6.53 |
| 2024 | $0.28 | −$3.72 | $0.00 | −$3.21 | — | $3.36 |
| 2025 | $1.99 | −$3.29 | $0.00 | −$3.73 | — | $0.74 |